Liquidia (NASDAQ:LQDA) Research Coverage Started at Scotiabank

Scotiabank assumed coverage on shares of Liquidia (NASDAQ:LQDA) in a research note issued to investors on Wednesday morning, MarketBeat.com reports. The brokerage issued a sector outperform rating and a $30.00 target price on the stock.

Several other brokerages have also issued reports on LQDA. Oppenheimer started coverage on Liquidia in a research report on Tuesday, June 25th. They issued a “market perform” rating for the company. Bank of America lowered their target price on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Lifesci Capital assumed coverage on Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target on the stock. Raymond James raised Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. Finally, HC Wainwright dropped their target price on Liquidia from $32.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

Liquidia Price Performance

NASDAQ LQDA opened at $11.14 on Wednesday. The business has a 50 day simple moving average of $10.41 and a 200 day simple moving average of $11.94. The stock has a market capitalization of $851.25 million, a P/E ratio of -7.14 and a beta of 0.22. Liquidia has a one year low of $5.71 and a one year high of $16.99.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $3.66 million during the quarter, compared to analysts’ expectations of $7.92 million. Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. Equities analysts expect that Liquidia will post -1.69 earnings per share for the current year.

Insider Activity at Liquidia

In other Liquidia news, insider Rajeev Saggar sold 2,260 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the transaction, the insider now owns 207,383 shares of the company’s stock, valued at approximately $2,304,025.13. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Roger Jeffs sold 8,053 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $89,468.83. Following the completion of the sale, the chief executive officer now directly owns 812,193 shares of the company’s stock, valued at $9,023,464.23. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Rajeev Saggar sold 2,260 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $25,108.60. Following the transaction, the insider now owns 207,383 shares of the company’s stock, valued at approximately $2,304,025.13. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 20,858 shares of company stock valued at $228,724 in the last ninety days. Corporate insiders own 31.60% of the company’s stock.

Institutional Trading of Liquidia

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Whitcomb & Hess Inc. increased its stake in Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after buying an additional 1,074 shares during the period. American International Group Inc. grew its position in Liquidia by 5.2% in the 1st quarter. American International Group Inc. now owns 24,806 shares of the company’s stock worth $366,000 after purchasing an additional 1,215 shares during the last quarter. Arizona State Retirement System increased its stake in Liquidia by 10.7% during the second quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock valued at $166,000 after acquiring an additional 1,341 shares during the period. Bleakley Financial Group LLC raised its stake in shares of Liquidia by 6.6% in the first quarter. Bleakley Financial Group LLC now owns 33,250 shares of the company’s stock valued at $490,000 after purchasing an additional 2,057 shares in the last quarter. Finally, Quest Partners LLC acquired a new position in shares of Liquidia in the 2nd quarter valued at $27,000. 64.54% of the stock is currently owned by institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).